
Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial
Hengrui Pharmaceuticals has announced that their camrelizumab combination therapy has doubled the five-year survival in a phase 3 trial of patients with advanced squamous lung cancer, according to a press release from the drug’s manufacturer. The five-year …